HeartSciences Inc., a healthcare information technology company focused on AI-enhanced electrocardiography, disclosed in its Form 10-K for the fiscal year ended April 30, 2026, that its independent registered public accounting firm included a going concern explanatory paragraph in its audit report. The disclosure signals that the company’s financial condition raises substantial doubt about its ability to continue operating without securing additional capital.
The company has a history of recurring losses and negative cash flows from operations, a pattern it expects to continue as it pursues regulatory clearance for its MyoVista wavECG device and works to commercialize its MyoVista Insights cloud-based ECG management platform. HeartSciences stated in the filing that it will require additional funding to support working capital, continued development and commercialization of MyoVista Insights, and the FDA review process for the MyoVista wavECG device and associated AI-ECG algorithms.
Platform Progress and Regulatory Pathway
HeartSciences has shifted its primary focus toward MyoVista Insights, a vendor-agnostic, cloud-native ECG management platform designed to streamline workflows and host AI-ECG algorithms from multiple developers. The platform received Epic Toolbox designation in March 2026, which the company believes may facilitate adoption within health systems that use Epic’s electronic health record software. A significant version upgrade released in the same month added mobile access, enhanced reporting, and expanded interoperability features.
The company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025. That submission remains under review, and the filing makes clear that there can be no assurance regarding the timing or outcome. HeartSciences also noted that it elected to separate the FDA submission for the device from the submission for its impaired cardiac relaxation algorithm after updated clinical guidelines from the American Society of Echocardiography revised age-based thresholds, requiring additional development and validation work.
Financial Position and Capital Needs
The going concern warning reflects the reality that HeartSciences has not yet generated meaningful revenue and remains dependent on external financing to fund operations. The company’s market capitalization stood at approximately $10.4 million as of the end of its second fiscal quarter. With the MyoVista wavECG device still under FDA review and the MyoVista Insights platform in early commercial deployment, the company’s near-term financial trajectory depends on its ability to secure additional funding while advancing both regulatory and commercial milestones.
HeartSciences is pursuing a SaaS-based revenue model for MyoVista Insights, with expected revenue from installation fees, usage fees, and fees from AI-ECG algorithms made available through its planned marketplace. The company is also in discussions with third-party algorithm developers regarding hosting and commercialization arrangements. Whether these initiatives can generate sufficient revenue to address the going concern uncertainty remains to be seen.